Detalhe da pesquisa
1.
Phosphorylation of cyclin dependent kinase 4 on tyrosine 17 is mediated by Src family kinases.
FEBS J
; 275(12): 3099-109, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18479465
2.
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Oncotarget
; 7(3): 2329-42, 2016 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26295308
3.
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).
J Med Chem
; 59(11): 5221-37, 2016 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27167172
4.
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.
Clin Cancer Res
; 18(20): 5650-61, 2012 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22929806
5.
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
J Med Chem
; 55(22): 10229-40, 2012 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-23082860
6.
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Clin Cancer Res
; 18(14): 3912-23, 2012 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22781553
7.
CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.
Cancer Res
; 71(2): 463-72, 2011 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21239475
8.
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
Mol Cancer Ther
; 10(2): 360-71, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21191045
9.
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
Mol Cancer Ther
; 9(1): 89-100, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20053762